Articles by Cynthia Challener, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Cynthia Challener, PhD

Process Design Is Critical for Commercial Manufacture of HPAPIs

Increasing potency and growing interest in antibody-drug conjugates are creating challenges for manufacturers of HPAPIs.
May 2, 2014

Increasing potency and growing interest in antibody-drug conjugates are creating challenges for manufacturers of HPAPIs.

Advances in Continuous Biopharmaceutical Manufacturing

Both upstream and downstream processes can benefit from continuous manufacturing advantages.
Apr 16, 2014

Both upstream and downstream processes can benefit from continuous manufacturing advantages.

Appropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs

Increasing potency and growing interest in antibody-drug conjugates are creating challenges for manufacturers of HPAPIs.
Apr 2, 2014

Increasing potency and growing interest in antibody-drug conjugates are creating challenges for manufacturers of HPAPIs.

Increased Efficiency Key to Competitiveness in Downstream Bioprocessing

Higher antibody titers and a growing demand for smaller-volume, flexible processes are creating the need for more cost-effective downstream processing.
Apr 2, 2014

Higher antibody titers and a growing demand for smaller-volume, flexible processes are creating the need for more cost-effective downstream processing.

Drug Delivery Technologies Provide Growth Opportunities for Biopharmaceuticals

Advanced drug delivery technologies can increase efficacy and safety, extend patent lives, and provide competitive differentiation for biopharmaceuticals.
Apr 1, 2014

Advanced drug delivery technologies can increase efficacy and safety, extend patent lives, and provide competitive differentiation for biopharmaceuticals.

Synthetic Biology Stirs Interest in Greener, More Efficient Processes

The commercial availability of an increasing diversity of enzymes has led to the growing use of biocatalysts for API synthesis.
Apr 1, 2014

The commercial availability of an increasing diversity of enzymes has led to the growing use of biocatalysts for API synthesis.

Synthetic Biology: The Next Frontier in Chiral Chemistry for API Synthesis

The commercial availability of an increasing diversity of enzymes has led to the growing use of biocatalysts for API synthesis.
Mar 2, 2014

The commercial availability of an increasing diversity of enzymes has led to the growing use of biocatalysts for API synthesis.

Regulatory Initiatives Spur API Supply Chain Security

Several recent regulatory initiatives designed to secure the global pharmaceutical supply chain have been implemented or are in the process of being adopted.
Feb 28, 2014

In order to ensure a safe drug supply chain, governments have implemented both legislated and voluntary programs designed to address problem areas.

Demand Increases for Novel Excipients, but Manufacturers Still Face Challenges

Feb 28, 2014

Drug formulators are looking for new excipients to address solubility and bioavailability issues and extend patent protection, but there are hurdles to using novel, specialized ingredients.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
FindPharma Custom Search
Click here